Article

AAO 2019 Retina Street Team: J. Fernando Arevalo, MD, FACS

J. Fernando Arevalo, MD, FACS, shares findings from his presentation on using brolucizumab to treat neovascular age-related macular degeneration (AMD), and whether the novel therapy is better than current treatment, at the 2019 annual meeting of the American Academy of Ophthalmology in San Francisco.

Day 3 of the 2019 annual meeting of the American Academy of Ophthalmology features Fernando Arevalo, MD, FACS, as he shares findings from his presentation on using brolucizumab to treat neovascular age-related macular degeneration (AMD), and whether the novel therapy is better than current treatment. 

Read and watch more AAO 2019 Retina Street Team coverage here

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
© 2025 MJH Life Sciences

All rights reserved.